LIGASORB® is a selective single-use, multiple-pass IgG adsorber for intervening in the acute exacerbation of autoimmune diseases.1
LIGASORB® offers flexible therapy schemes for acute episodes of antibody driven diseases.
LIGASORB® offers full flexibility where therapy schemes only require a few treatment sessions, as is the case in acute episodes of the following antibody driven diseases:
LIGASORB® is the first Fresenius Medical Care adsorber that can be regenerated during ongoing therapy (multiple-pass) but disposed of after one treatment session (single-use).
In contrast to therapeutic plasma exchange, only a small amount of other essential plasma components (such as albumin) are removed during immunoadsorption.
Due to its highly selective protein A ligand and regeneration capabilities, LIGASORB® is able to process up to six litres of plasma and remove up to 20 grams of IgG in a single treatment session.
The total IgG reduction after three treatment sessions is 86% (mean value).7